Document is current

Article History

Received: 6 May 2025

Accepted: 1 July 2025

First Online: 24 July 2025

Disclosure

: Rita A. Mukhtar reports research funding from GE Healthcare. A. Jo Chien reports institutional research funding from Merck, Amgen, Puma, Seagen, Pfizer, Olema; and advisory roles with AstraZeneca and Genentech. Kamran Ahmed reports institutional research funding from Eli Lilly, Genentech, and Gilead. Lily Gutnik reports research funding from the American Society of Clinical Oncology (ASCO) and the National Cancer Institute (NCI); and is an unpaid advisory board member for the Know Your Lemons Foundation and PretacPlus. M. Catherine Lee reports I-SPY2 trial funding, paid to her institution. Angela DeMichele reports institutional research funding from Novartis, Pfizer, Genentech, and Neogenomics; and serves as Program Chair for the Scientific Advisory Committee at ASCO. Douglas Yee reports research funding from National Institutes of Health (NIH)/NCI P30 CA 077598, P01 CA234228-01 and R01CA251600; consulting fees from Martell Diagnostics; and honoraria and travel for speaking at the International Breast Cancer Conference. Nola M. Hylton reports institutional research funding from the NIH. W. Fraser Symmans reports shares in IONIS Pharmaceuticals and Eiger Biopharmaceuticals; has received consulting fees from AstraZeneca; is a co-founder with equity in Delphi Diagnostics; and has issued patents for (1) a method to calculate residual cancer burden, and (2) genomic signature to measure sensitivity to endocrine therapy. Chantal Reyna reports Elucent and agenda consulting, terminated 2022. Hope S. Rugo reports institutional research support from AstraZeneca, Daiichi Sankyo, Inc., F. Hoffmann-La Roche AG/Genentech, Inc., Gilead Sciences, Inc., Lilly, Merck & Co., Novartis Pharmaceuticals Corporation, Pfizer, Stemline Therapeutics, OBI Pharma, Ambrx, and Greenwich Pharma; and advisory and consulting roles with Chugai, Puma, Sanofi, Napo, and Mylan. MD reports receiving research grants from the NIH/NCI and NIH/National Institute on Aging (NIA), and contracts from the Patient-Centered Outcomes Research Institute (PCORI). Rebecca Shatsky reports institutional research funding from OBI Pharmaceuticals, Quantum Leap Healthcare Collaborative, AstraZeneca and Gilead; serves on the AstraZeneca and Stemline Advisory Boards and the Gilead Speaker’s Bureau; has undertaken a consultancy role with Quantum Leap Healthcare Collaborative; and declares consulting/advisory roles for Novartis, Lilly, AstraZeneca, Daiichi Sankyo, Stemline, and Gilead. Claudine Isaacs reports institutional research funding from Tesaro/GSK, Seattle Genetics, Pfizer, AstraZeneca, BMS, Genentech, Novartis, and Regeneron; consultancy roles with AstraZeneca, Genentech, Gilead, ION, Merck, Medscape, MJH Holdings, Novartis, Pfizer, PUMA, Seagen; and royalties from Wolters Kluwer (UptoDate), and McGraw Hill (Goodman and Gillman). Laura J. Esserman reports participation on the Blue Cross Medical Advisory Panel; and is an uncompensated board member of Quantum Leap Healthcare Collaborative. Laura J. van 't Veer is a founding advisor and shareholder of Exai Bio; and part-time employee of, and owns stock in, Agendia. Judy C. Boughey receives institutional research funding from Eli Lilly, SimBioSys and Quantum Leap Healthcare; and serves on the Data Safety Monitoring Board for Cairn Surgical. Katrina Dimitroff, Christina Yau, Eileen P. Connolly, Marissa Howard-McNatt, Roshni Rao, Velle Ladores, Mehra Golshan, Candice A. Sauder, Rachael Lancaster, Jana Fox, Julia Tchou, Nicolas Prionas, Cletus A. Arciero, Henry Kuerer, Kayla Switalla, Neil Taunk, Todd M. Tuttle, Meena S. Moran, Lauren M. Postlewait, and Jane Perlmutter declare no competing interests that may be relevant to the contents of this study.